Cargando…

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma

Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosner, Samuel, Agrawal, Yuri, Sun, Daniel Q, Aygun, Nafi, Schollenberger, Megan D, Lipson, Evan, Naidoo, Jarushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745691/
https://www.ncbi.nlm.nih.gov/pubmed/33335030
http://dx.doi.org/10.1136/jitc-2020-001675
_version_ 1783624655435726848
author Rosner, Samuel
Agrawal, Yuri
Sun, Daniel Q
Aygun, Nafi
Schollenberger, Megan D
Lipson, Evan
Naidoo, Jarushka
author_facet Rosner, Samuel
Agrawal, Yuri
Sun, Daniel Q
Aygun, Nafi
Schollenberger, Megan D
Lipson, Evan
Naidoo, Jarushka
author_sort Rosner, Samuel
collection PubMed
description Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treated patients who developed immune-mediated ototoxicity, identified by a multidisciplinary immune-related toxicity team. This is the largest case series to date and identifies bilateral high-frequency hearing loss and tinnitus as the most common reported symptoms and can be associated with abnormal speech reception thresholds and word recognition ability on audiogram in select patients. We propose multidisciplinary evaluation of patients with suspected otologic irAEs including referral to otolaryngology, audiometry evaluation±magnetic resonance imaging for evaluation of suspected immune-mediated ototoxicity.
format Online
Article
Text
id pubmed-7745691
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77456912020-12-28 Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma Rosner, Samuel Agrawal, Yuri Sun, Daniel Q Aygun, Nafi Schollenberger, Megan D Lipson, Evan Naidoo, Jarushka J Immunother Cancer Case Report Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treated patients who developed immune-mediated ototoxicity, identified by a multidisciplinary immune-related toxicity team. This is the largest case series to date and identifies bilateral high-frequency hearing loss and tinnitus as the most common reported symptoms and can be associated with abnormal speech reception thresholds and word recognition ability on audiogram in select patients. We propose multidisciplinary evaluation of patients with suspected otologic irAEs including referral to otolaryngology, audiometry evaluation±magnetic resonance imaging for evaluation of suspected immune-mediated ototoxicity. BMJ Publishing Group 2020-12-16 /pmc/articles/PMC7745691/ /pubmed/33335030 http://dx.doi.org/10.1136/jitc-2020-001675 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Case Report
Rosner, Samuel
Agrawal, Yuri
Sun, Daniel Q
Aygun, Nafi
Schollenberger, Megan D
Lipson, Evan
Naidoo, Jarushka
Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
title Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
title_full Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
title_fullStr Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
title_full_unstemmed Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
title_short Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
title_sort immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745691/
https://www.ncbi.nlm.nih.gov/pubmed/33335030
http://dx.doi.org/10.1136/jitc-2020-001675
work_keys_str_mv AT rosnersamuel immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma
AT agrawalyuri immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma
AT sundanielq immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma
AT aygunnafi immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma
AT schollenbergermegand immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma
AT lipsonevan immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma
AT naidoojarushka immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma